Genetic Technologies Ltd

Diversified molecular diagnostics company Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE) is engaged in developing risk assessment tests based on genetic technology. The Company provides tests to predict an individual’s risk of developing a chronic indication. Genetic Technologies offers predictive testing as well as assessment tools for cancers and other diseases to aid physicians in proactively managing patient health.

GTG is developing a product pipeline of first-in-class, clinically validated risk assessment tests. The diagnostic Company is working to enhance the health outcomes for people across the globe by offering risk assessment tools to develop personalised health management strategies to detect and treat chronic diseases.​

The Company continually strives to maintain its position as a global leader in the genomics industry by investing in its research capabilities and collaborations with experts from world-class organisations, including universities, research organisations, and progressive medical product distribution companies.

Genetic Technologies owns and operates a world-class Clinical Laboratory Improvement Amendments (CLIA) authorised laboratory in Melbourne, Australia. The Company has collaborative agreements with other laboratory operators worldwide for ensuring the availability of its world-class genetic tests in selected jurisdictions.

GTG’s lead products include GeneType for Breast Cancer and GeneType for Colorectal Cancer.

GeneType for Breast Cancer (non-hereditary breast cancer)

GeneType for Breast Cancer can determine the risk of a woman developing sporadic breast tumour over a period. Three key factors contributing to the risk of developing sporadic breast cancer include genetic markers, family history, and breast density.

GeneType for Breast Cancer combines all the risk factors to offer a more accurate assessment of the risk of developing breast cancer.

GeneType for Colorectal Cancer

GeneType test for Colorectal Cancer can determine the risk of developing colorectal tumour over a period. The test combines several factors, including the patient’s family history, age, and genetic markers, to provide a more precise assessment of the risk of developing colorectal cancer.

The Company is also developing risk assessment test for type 2 diabetes, cardiovascular indications, prostate cancer, melanoma, and COVID-19.